Cerebrospinal fluid biomarker for Parkinson's disease: An overview

Fabian Maass; Isabel Schulz; Paul Lingor; Brit Mollenhauer; Mathias Bähr

doi:10.1016/j.mcn.2018.12.005

Cerebrospinal fluid biomarker for Parkinson's disease: An overview

Fabian Maass, Isabel Schulz, Paul Lingor, Brit Mollenhauer, Mathias Bähr

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.

Original language	English
Pages (from-to)	60-66
Number of pages	7
Journal	Molecular and Cellular Neuroscience
Volume	97
DOIs	https://doi.org/10.1016/j.mcn.2018.12.005
State	Published - Jun 2019
Externally published	Yes

Keywords

Biomarker
CSF
Parkinson's disease

Access to Document

10.1016/j.mcn.2018.12.005

Cite this

@article{1e8d23091f18480e9466975ecf30e649,

title = "Cerebrospinal fluid biomarker for Parkinson's disease: An overview",

abstract = "In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.",

keywords = "Biomarker, CSF, Parkinson's disease",

author = "Fabian Maass and Isabel Schulz and Paul Lingor and Brit Mollenhauer and Mathias B{\"a}hr",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = jun,

doi = "10.1016/j.mcn.2018.12.005",

language = "English",

volume = "97",

pages = "60--66",

journal = "Molecular and Cellular Neuroscience",

issn = "1044-7431",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Cerebrospinal fluid biomarker for Parkinson's disease

T2 - An overview

AU - Maass, Fabian

AU - Schulz, Isabel

AU - Lingor, Paul

AU - Mollenhauer, Brit

AU - Bähr, Mathias

PY - 2019/6

Y1 - 2019/6

N2 - In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.

AB - In Parkinson's disease (PD), there is a wide field of recent and ongoing search for useful biomarkers for early and differential diagnosis, disease monitoring or subtype characterization. Up to now, no biofluid biomarker has entered the daily clinical routine. Cerebrospinal fluid (CSF) is often used as a source for biomarker development in different neurological disorders because it reflects changes in central-nervous system homeostasis. This review article gives an overview about different biomarker approaches in PD, mainly focusing on CSF analyses. Current state and future perspectives regarding classical protein markers like alpha‑synuclein, but also different “omics” techniques are described. In conclusion, technical advancements in the field already yielded promising results, but further multicenter trials with well-defined cohorts, standardized protocols and integrated data analysis of different modalities are needed before successful translation into routine clinical application.

KW - Biomarker

KW - CSF

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85058370215&partnerID=8YFLogxK

U2 - 10.1016/j.mcn.2018.12.005

DO - 10.1016/j.mcn.2018.12.005

M3 - Review article

C2 - 30543858

AN - SCOPUS:85058370215

SN - 1044-7431

VL - 97

SP - 60

EP - 66

JO - Molecular and Cellular Neuroscience

JF - Molecular and Cellular Neuroscience

ER -

Cerebrospinal fluid biomarker for Parkinson's disease: An overview

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this